M
Mersana Therapeutics D
D
MRSN
6.88000
USD
6.57
(2,126.54%)
مغلق
حجم التداول
6,168
الربح لكل سهم
-2
العائد الربحي
-
P/E
-0
حجم السوق
857,463,612
الأخبار المقالات
العنوان: Mersana Therapeutics Inc
القطاع: Healthcare
الصناعة: Biotechnology
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADCplatforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.